BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
POMPANO BEACH, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products.
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
BioStem Technologies to Sponsor MRO Better Half Dash
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
BioStem Technologies Granted Prioritized Examination for Wound Healing Patent
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts